Abstract

AN OVERVIEW OF CANAGLIFLOZIN

Adarsha Ganguly, Aveek Datta*, Mayukh Jana, Dr. Biplab Debnath, Mrs. Mohini Mondal

ABSTRACT

Introduction: Besides improving glycemic control, SGLT2is have disclosed the renal and heart failure benefits in T2D patients, according to the systematic review. Canagliflozin belongs to the family of SGLT2is, and it has been clinically verified to provide positive effects in heart and renal issues with a decreased chance of stroke and Cardiovascular Disease all-in-one composite indicators. Expert Opinion: Thus, canagliflozin is useful to inhibit renal function and decline progression for patients with T2D above the age of 40 having chronic renal impairment and proteinuria.. A Canagliflozin Cardiac Evaluation trial display of a real-world data of usage by researchers reveled that patients experienced a higher rate of amputation through unrecognized causes. Also, it has been evidenced that canagliflozin has advantages within anemia side-effects of chronic renal failure. Where opposed to other SGLT2is, a positive effect on diastolic blood pressure was established for canagliflozin through the meta-analysis. From a subanalysis of the CANVAS study, it was expounded that the rate of hemorrhagic stroke had significantly reduced among patients who took canagliflozin. Canagliflozin is recommended in a patient with chronic renal failure or albuminuria or vascular disease accompanying the type 2 diabetes; however, these patients should be observed for ulcer and/or lower limb pulse closely.

Keywords: Diabetes, Canagliflozin, Sodium glucose-co transporter, CANVAS, Invokana, renal, cardiac.